AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

0.59USD
26 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
$0.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,973,002
52-wk High
$1.62
52-wk Low
$0.48

AEZS.O

Chart for AEZS.O

About

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in... (more)

Overall

Beta: 1.38
Market Cap (Mil.): $33.90
Shares Outstanding (Mil.): 57.89
Dividend: --
Yield (%): --

Financials

  AEZS.O Industry Sector
P/E (TTM): -- 159.35 38.84
EPS (TTM): -0.65 -- --
ROI: -70.99 -0.82 18.26
ROE: -254.20 -1.98 19.12
Search Stocks

Aeterna hits record low after FDA rejects growth hormone test

- Canada's Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, which the drugmaker had hoped would be the first orally administered drug to determine if adults had growth hormone deficiency.

06 Nov 2014

UPDATE 2-Aeterna hits record low after FDA rejects growth hormone test

* FDA says not enough "verifiable" data, asks for fresh trial

06 Nov 2014

FDA rejects Aeterna's growth hormone diagnostic test

Nov 6 - Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, an experimental test designed to determine if adults' pituitary glands are secreting enough growth hormone.

06 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: GlobalData
$125.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks